Ceregene Promotes Dr. Raymond Bartus to Executive Vice President

Dec 06, 2007, 00:00 ET from Ceregene, Inc.

    SAN DIEGO, Dec. 6 /PRNewswire/ -- Ceregene, Inc. today announced the
 promotion of Raymond T. Bartus, Ph.D., to the position of executive vice
 president of clinical and preclinical R&D and chief operating officer.
 Since joining Ceregene in 2002, Dr. Bartus has led the preclinical and
 clinical development efforts for CERE-120 and CERE-110, Ceregene's programs
 for Parkinson's disease and Alzheimer's disease, respectively. These
 efforts have included overseeing the development of well-designed Phase 2
 clinical trial protocols as well as the management of clinical trial sites.
 Dr. Bartus has also led the preclinical development efforts in our gene
 therapy programs that target neurotrophic factors for the treatment of
 amyotrophic lateral sclerosis (Lou Gehrig's disease) and ocular diseases.
 Dr. Bartus formerly held the position of senior vice president of clinical
 and preclinical R&D and chief operating officer.
     "We are pleased to announce Ray's well-deserved promotion today, as he
 has been a tremendous contributor and leader within Ceregene," stated
 Jeffrey M. Ostrove, Ph.D., president and chief executive officer of
 Ceregene. "Ray has been a key driver behind our CERE-120 and CERE-110
 programs. His focused efforts have enabled us to move these promising
 programs through clinical development, the furthest of which-CERE-120-could
 enter Phase 3 trials for Parkinson's disease in 2009."
     Dr. Bartus, a pioneer in the neuroscience industry, is the co-developer
 of the Cholinergic Theory of Alzheimer's Disease -- a theory demonstrating
 the relevance of cholinergic neurons in the disease process of Alzheimer's
 disease, which is highly relevant to CERE-110, Ceregene's product candidate
 for Alzheimer's disease as well as the majority of drugs on the market
 today for Alzheimer's disease. Dr. Bartus brought nearly 30 years of
 neuroscience expertise to Ceregene and has built and directed several
 research teams at both large multi-national pharmaceutical companies and
 small start-up companies. Under his leadership, his groups have
 successfully identified and developed novel compounds, many of which have
 advanced through clinical development and licensure. Additionally, Dr.
 Bartus has maintained a strong scientific presence and continuous academic
 affiliations during his career, which include adjunct academic appointments
 and collaborations, editorial responsibility and a publication record
 involving approximately 250 manuscripts. Dr. Bartus is the founding editor
 and inaugural editor-in-chief of the scholarly journal, Neurobiology of
 Aging: Experimental and Clinical Research.
     About Ceregene
     Ceregene, Inc. is a San Diego-based biotechnology company focused on
 the delivery of nervous system growth factors for the treatment of
 neurodegenerative disorders using gene delivery. Ceregene's clinical
 programs include CERE-110, an AAV2 based vector expressing nerve growth
 factor that is currently in Phase 1/2 studies for the treatment of
 Alzheimer's disease, and CERE-120 (AAV2-Neurturin) which recently completed
 enrollment of a controlled Phase 2 study for Parkinson's disease. CERE-130
 and CERE-140 are in preclinical development for ALS (Lou Gehrig's disease)
 and ocular disorders, respectively. Ceregene was launched in January 2001
 and is a former subsidiary of Cell Genesys, Inc. (Nasdaq:   CEGE). The
 company's investors include Alta Partners, MPM Capital, Investor Growth
 Capital and Cell Genesys as well as Hamilton BioVentures and California
 Technology Partners.

SOURCE Ceregene, Inc.